Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics (NasdaqCM:CORT) saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31, ...

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing’s syndrome) and prostate cancer. Relacorilant is ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...

Mid-cap stocks surged in the past week, including CORT, COOP, and CRWV. GOOG may rent AI servers from CRWV. PRGS and LOAR ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics (CORT) to $131 from $128 and keeps an Overweight ...

It's tempting to think some magic number will guarantee that a stock will go up or down. But the hard reality is that Wall Street is as much of an expectations game as anything else.